**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 52932

**Manuscript Type:** Letter to the Editor

**Results of meta-analysis should be treated critically**

Liu RQ *et al*. Important Results of meta-analysis

Rong-Qiang Liu, Yi Shao

**Rong-Qiang Liu,** Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China

**Rong-Qiang Liu,** Department of hepatobiliary surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510220, Guangdong Province, China

**Yi Shao,** Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China

**Author contributions:** Liu RQ and Shao Y designed and performed the research, and analyzed the data; Liu RQ wrote the letter; Liu RQ revised the letter.

**Supported by** National Natural Science Foundation of China, No. 81400372; Youth Science Foundation of Jiangxi Province, No. 20151BAB21516; Science and Technology Plan Project of Jiangxi Province, No. 20151BBG70223; Association for Science and Technology of Jiangxi Province, No. 20111BBG70026-2; Science and Technology Plan of Jiangxi Provincial Health and Family Planning Commission, No. 20164017 and No. 20155154.

**Corresponding author: Yi Shao, MD, PhD, Director, Doctor,** Department of ophthalmology, The First Affiliated Hospital of Nanchang University, No. 17, YongWaiZheng Street, DongHu District, Nanchang 330006, Jiangxi Province, China. freebee99@163.com

**Received:** November 25, 2019

**Revised:** January 14, 2020

**Accepted:** January 19, 2020

**Published online:** March 7, 2020

**Abstract**

Proton pump inhibitors use increases hepatic encephalopathy risk in patients with liver disease.

**Key words:** Proton pump inhibitor; Hepatic encephalopathy; Liver disease

**Citation:** Liu RQ, Shao Y. Results of meta-analysis should be treated critically. *World J Gastroenterol* 2020; 26(9): 992-994

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i9/992.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i9.992

**Core tip:** Proton pump inhibitors (PPIs) have been widely used in patients with liver disease. In general, PPIs are considered safe. However, accumulating evidence indicates that long-term and excessive use of PPIs without clear indication can lead to serious adverse reactions. Some epidemiological studies have investigated the association of PPI use with the risk of hepatic encephalopathy. However, the results are controversial. The study reveals that PPI use increases hepatic encephalopathy risk in patients with liver disease. This reminds clinicians to be more cautious when using PPIs in patients with liver disease.

**To the Editor**

We read the recently published meta-analysis on the association between proton pump inhibitor (PPI) and hepatic encephalopathy (HE)[[1](#_ENREF_1)]. The authors found that there was a significant association between PPI use and HE risk with low heterogeneity (*I*2 = 14.2%). In fact, a correct analysis showed an even stronger association. First, the author made an error in extracting the data. The study by Tsai *et al*[2] provided three dose-related odds ratios (ORs) of 1.41 (1.09-1.84), 1.51 (1.11-2.06) and 3.01 (1.78-5.10), and the meta-analysis by Ma *et al*[1] incorrectly used only the first OR. According to the study of Hamling *et al*[3], we recalculated that the correct OR was 1.59 (1.30-1.95). The results of the meta-analysis revealed that PPI use was significantly associated with the risk of HE with a pooled OR of 1.97 (95% confidence interval [CI]: 1.51–2.58) by using a random effects model (*I*2 = 57.1%). The forest plot is shown in Figure 1. In addition, we used the data which were given by Ma *et al*[1] to perform comprehensive analysis. The pooled OR was 1.97 (1.47, 2.65) instead of 1.50 (1.25, 1.75) and the *I*2 was 61.2% instead of 14.2%. The results are shown in Figure 2. The incorrect operations of Ma *et al*[1] from using software may be the cause of inconsistencies. Due to the obvious heterogeneity, subgroup analysis and meta-regression should be performed to explore the sources of heterogeneity.

The fixed effects model assumes that all the included studies have the same true effect size, while the true effect size in the random effects model varies with different studies. When the observed effect size of each study approaches or equals its true effect size, the heterogeneity is not obvious and the fixed effect model should be used. Otherwise, the random effects model is used. The Cochrane Handbook has stated that when *I*2 is less than 40%, a fixed effects model should be used for meta-analysis. Otherwise, a random effect model should be used. In general, the conclusions obtained by random effects models tend to be conservative, and thus can be used in any case. However, when the heterogeneity is significant, only the random effect model can be used, and further analysis is needed to find the sources of heterogeneity.

In conclusion, our results demonstrated that PPI use increased HE risk, consistent with the study of Ma *et al*[1]. However, the meta-analysis by Ma *et al*[1] is flawed. More accurate statistical analysis is necessary to improve the quality of this meta-analysis.

**REFERENCES**

1 **Ma YJ**, Cao ZX, Li Y, Feng SY. Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis. *World J Gastroenterol* 2019; **25**: 2675-2682 [PMID: 31210718 DOI: 10.3748/wjg.v25.i21.2675]

2 **Tsai CF**, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, Hou MC, Lee FY, Su TP, Lu CL. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. *Gastroenterology* 2017; **152**: 134-141 [PMID: 27639806 DOI: 10.1053/j.gastro.2016.09.007]

3 **Hamling J**, Lee P, Weitkunat R, Ambühl M. Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. *Stat Med* 2008; **27**: 954-970 [PMID: 17676579 DOI: 10.1002/sim.3013]

**Footnotes**

**Conflict-of-interest statement:** Osamu Yokosuka has received research funding from Chugai Pharma.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** November 25, 2019

**First decision:** December 23, 2019

**Article in press:** January 19, 2020

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Barreto SG, Chiu CC, Triantafyllou K **S-Editor:** Zhang L **L-Editor:** Filipodia **E-Editor:** Ma YJ

**Figure Legends**

****

**Figure 1 Forest plot of the association between proton pump inhibitor use and hepatic encephalopathy.**

****

**Figure 2 Forest plot of proton pump inhibitor use and risk of hepatic encephalopathy.**